Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02455882 · ClinicalTrials.gov registry record
Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast Cancer
A clinical trial, sponsored by University of Michigan.
- Terminated
- Registry status
- 14
- Enrollment target
NCT02455882: Clinical Trial study, sponsored by University of Michigan.
NCT02455882 is a clinical trial that was terminated before completion, run by University of Michigan. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02455882 was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- 14 participants
- Enrollment target
Study Summary
Through the investigators' Breast Care Center at the University of Michigan Comprehensive Cancer Center, the investigators treat approximately 75 patients per year with neoadjuvant chemotherapy. The majority of the remainder of patients with stage II and III disease undergo treatment with adjuvant chemotherapy either on a clinical protocol or as standard of care. There is a subset of women with ER positive disease who do not receive chemotherapy because of favorable tumor characteristics. This tissue procurement protocol is designed to systematically collect tissue, urine and blood specimens on patients undergoing neoadjuvant systemic therapy or adjuvant chemotherapy, serially following treatment, and/or at the time of disease recurrence in order to investigate mechanisms underlying development of metastatic disease, to identify predictors of response and resistance to therapy, and to test potential new therapies for breast cancer using a combination of patient-derived xenograft creation and new microfluidic technologies.
Primary Outcome
Mutations in the tumor before and after primary systemic therapy will be examined
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-05-30 |
| Est. Completion | 2017-04-07 |
Why NCT02455882 stopped before completion
NCT02455882 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02455882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02455882 about?
NCT02455882 is a clinical study titled "Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast Cancer". Through the investigators' Breast Care Center at the University of Michigan Comprehensive Cancer Center, the investigators treat approximately 75 patients per year with neoadjuvant chemotherapy. The majority of the remainder of patients with stage II and III disease undergo treatment with adjuvant c...
What is the current status of trial NCT02455882?
This trial is currently terminated. The enrollment target is 14 participants. The study started on 2014-05-30. Estimated completion is 2017-04-07.
Who is sponsoring clinical trial NCT02455882?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy